{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Metabolic Enzyme & Protease > LinagliptinCAS：668270-12-0
Molecular Formula：C25H28N8O2
Molecular Weight：472.54
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 668270-12-0 |
| Name | Linagliptin |
| Molecular Formula | C25H28N8O2 |
| Molecular Weight | 472.54 |
| Solubility | Soluble in DMSO ≥10mg/mL |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 1308068-626-2 |
| MDL | MFCD14635356 |
| SMILES | CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C |
| InChIKey | LTXREWYXXSTFRX-QGZVFWFLSA-N |
| InChI | InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7，10-11，17H，8-9，12-15，26H2，1-3H3/t17-/m1/s1 |
| PubChem CID | 10096344 |
| Target Point | Dipeptidyl Peptidase(DPP-4) |
| Passage | Metabolic Enzyme&Protease |
| Background | Linagliptin is an effective and selective DPP-4 inhibitor. |
| Biological Activity | Linagliptin is a highly potent， selective DPP-4 inhibitor with IC50 of 1 nM.[1-4] |
| IC50 | IC50: 1 nM (DPP-4)[1-4] |
| Data Literature Source | [1]. Eckhardt M， et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3，7-dihydropurine-2，6-dione (BI 1356)， a highly potent， selective， long-acting， and orally bioavailable DPP-4 inhibitor for the treatment of type 2 d [2]. Thomas L， et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3，7-dihydro-purine-2，6-dione (BI 1356)， a novel xanthine-based dipeptidyl peptidase 4 inhibitor， has a superior potency and longer duration of action [3]. Schurmann C， et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. 2012 Jul;342(1):71-80. [4]. Huan Y， et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Sci Rep. 2017 Jun 28;7(1):4351. |
| Unit | Bottle |
| Specification | 5mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
